ALXO ALX ONCOLOGY HOLDINGS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.05

Period return

+0.58 (+39.46%)

Volume

723.5K

2026-07-21O $1.91 H $2.09 L $1.91 C $2.05MA5 $2.03MA20 $2.05MA60 $1.87MA120 $1.95

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 08.High2 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 03. 19.MediumBUY4 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 03. 10.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 02. 06.LowBUY6 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2025. 05. 21.LowBUYlast year
UBS: Buy
US analyst rating / recommendation change.
2025. 05. 09.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 08.LowHOLDlast year
Stifel: Hold
US analyst rating / recommendation change.
2025. 03. 07.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 06.LowBUYlast year
Piper Sandler: Overweight
US analyst rating / recommendation change.
2025. 03. 06.MediumBUYlast year
Jefferies: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $4.6 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
HQ: South San Francisco, CA, United States
Fiscal year end

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 05. 08.	After market close (AMC)	$-0.16	—	—	$0	—	Scheduled
FY2021 Q3	2020. 09. 30.	Time TBD	—	—	—	—	$1.18M	Reported
FY2021 Q2	2020. 06. 30.	Time TBD	—	—	—	—	$1.18M	Reported
FY2021 Q1	2020. 03. 31.	Time TBD	—	—	—	—	$655K	Reported

ALX ONCOLOGY HOLDINGS INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 03. 19.	Wells Fargo	—	Initiate coverage	— → Overweight	—	Wells Fargo: Overweight
2026. 03. 10.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 02. 06.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2025. 05. 21.	UBS	—	Maintain	Buy → Buy	—	UBS: Buy
2025. 05. 09.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 03. 08.	Stifel	—	Maintain	Hold → Hold	—	Stifel: Hold